Talaris Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TALS Nasdaq 8731 https://talaristx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Talaris Therapeutics Inc

Talaris Therapeutics Announces Leadership Transition - May 26th, 2023 11:00 am
Talaris Therapeutics, Inc. (NASDAQ:TALS) most popular amongst private equity firms who own 34% of the shares, institutions hold 30% - May 20th, 2023 12:18 pm
Wellesley biotech cuts one-third of staff, explores sale - Feb 16th, 2023 8:10 pm
Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan - Feb 16th, 2023 12:00 pm
We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully - Dec 25th, 2022 2:25 pm
Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference - Nov 22nd, 2022 12:00 pm
Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update - Nov 10th, 2022 12:00 pm
Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance - Nov 7th, 2022 12:00 pm
Talaris (TALS) Down on Patient Death From Renal Transplant Study - Oct 21st, 2022 3:28 pm
HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space - Oct 20th, 2022 6:27 pm
Talaris Therapeutics Reports Patient Death In Late-Stage Trial Of Experimental Drug For Graft vs Host Disease - Oct 20th, 2022 2:26 pm
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial - Oct 20th, 2022 11:00 am
Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting - Oct 17th, 2022 11:00 am
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa - Oct 4th, 2022 11:00 am
Talaris Therapeutics to Present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event - Sep 21st, 2022 11:00 am
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences - Sep 6th, 2022 11:00 am
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update - Aug 15th, 2022 11:00 am
We Think Talaris Therapeutics (NASDAQ:TALS) Can Afford To Drive Business Growth - Jul 18th, 2022 1:47 pm
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update - Jun 30th, 2022 11:00 am
Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022 - Jun 7th, 2022 8:01 pm